NEWS

Schlieren / Zurich, Switzerland – May 2, 2023 – Memo Therapeutics AG (“MTx”), a biotech company developing best-in-class therapeutic antibodies, announced today that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation to AntiBKV, MTx’s lead antibody therapeutic that targets BK polyomavirus (“BKV”) infection commonly seen in renal transplant patients. AntiBKV has successfully completed a phase I clinical study and following FDA clearance has started actively recruiting patients for a pivotal phase II/III clinical trial.

Schlieren / Zurich, Switzerland, and Osaka, Japan – November 1, 2022 – Memo Therapeutics AG (“MTx”), an innovator in the field of antibody discovery and development, announced today the signing of a research and development collaboration agreement with Ono Pharmaceutical Co. Ltd (“Ono”).

Schlieren, Switzerland – April 27, 2022 – Memo Therapeutics AG (“MTx”), an innovator in the field of antibody discovery and development, announced today the initiation of a phase 1 clinical study of COVAB 36, a potent, fully-human monoclonal antibody for the treatment of SARS-CoV-2 infections.

Schlieren, Switzerland – December 13, 2021 – Memo Therapeutics AG (“Memo”), an innovator in the field of antibody discovery and development, announced today the receipt of CHF 10.5 million from the Swiss Federal Funding Programme for COVID-19 Medicines to clinically develop COVAB 36, a potent, fully-human monoclonal antibody for the treatment of SARS-CoV-2 infections.

Schlieren, Switzerland – June 16, 2020 – Memo Therapeutics AG (“Memo”), an innovator in the field of antibody discovery and development, announced today the appointment of Dr. George Badita as Chief Medical Officer and Lars Spenger as Head of Finance and Administration.

Schlieren, Switzerland – December 3, 2020 – Memo Therapeutics AG, an innovator in the field of antibody discovery and development, announced today that MTX-COVAB, its human-derived antibody against SARS-CoV-2, the virus that causes COVID-19, has demonstrated outstanding efficacy in an animal model of the infection, both in a treatment and a prophylactic setting. MTX-COVAB was also found to have virus neutralizing potency (IC50= 40pM), which is comparable or better to that of the leading antibody therapies in development, and cross-neutralizes all clinically relevant virus mutants. MTX-COVAB is a fully human antibody isolated from clinically selected convalescent COVID-19 patients. Data have been made available on the bioRxiv.org pre-print server.

Schlieren, Switzerland, and Vilnius, Lithuania – August 11, 2020 – Swiss biotech company Memo Therapeutics AG (MTx), and Northway Biotechpharma (Northway), a leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announce a new partnership to develop a fast-track manufacturing path for MTx’s therapeutic COVID-19 antibody candidate.

Schlieren, Switzerland – 4 June 2020 – Memo Therapeutics AG (“MTx”), an innovator in the field of antibody discovery and immune repertoire analysis, today announces that it has identified several SARS-CoV-2-specific virus-neutralizing antibodies with the potential for development as a COVID-19 immunotherapy.

Düsseldorf, Germany and Schlieren, Switzerland October 25th, 2019. ImmunoQure AG, a biotechnology company focused on the development of autoantibodies as therapeutics to treat human diseases and Memo Therapeutics AG, a biotechnology company focused on the discovery and development of therapeutic antibodies from cognate paired antibody libraries today announced the establishment of a collaborative partnership to create libraries from APS-1 memory B cells.

Basel, Switzerland, Feb 1st, 2019 - This is a major step in the technology development at Memo Therapeutics AG since we are now able to directly screen antibody repertoire libraries from rare patients or immunized animals for antibodies with the desired functional activity in a single day.

Basel, Switzerland, May 9th 2018 – Memo Therapeutics AG (“MEMO”), an innovator in the field of antibody discovery and human immune repertoire analysis, announced today the closing of a Series A2 financing round of CHF 5.0 million.

Memo Therapeutics AG was awarded a new CTI grant

Memo Therapeutics AG at conferences

MEMO’s poster introducing the MemoMAB™ technology platform for the banking and screening of human...